A Cost-Effective Antibiotic For Hospital Acquired Pneumonia

Published Jun 30, 2014
Beijing, China - Linezolid is a relatively new approved antibiotic in China for the treatment of hospital-acquired pneumonia.  As linezolid has been shown to be a cost-effective alternative in comparison to vancomycin in many countries such as the USA, Germany and Brazil, researchers from IMS Health in Asia sought out to learn if superior efficacy of linezolid compared with vancomycin would be demonstrated in a head-to-head clinical study in China. As described in the article, “Cost-Effectiveness of Linezolid versus Vancomycin Among Patients with Methicillin-Resistant Nosocomial Pneumonia in China,” published in Value in Health Regional Issues, Volume 3, the researchers compared linezolid against branded vancomycin in terms of its cost-effectiveness value in treating methicillin-resistant hospital acquired pneumonia from the payer’s perspectives in Beijing, Nanjing, Guangzhou, and Xi’an. Through a simulation using clinical trial data, the probability of overall treatment success was predicted as 0.629 and 0.602 for linezolid and vancomycin, respectively. The total inpatient costs ranged from ¥58,835 to ¥86,894 for linezolid and ¥58,390 to ¥87,033 for vancomycin, respectively. Linezolid was demonstrated to be a dominant strategy resulting in cost-saving with better outcomes in Guangzhou and a cost-effective strategy in Beijing, Nanjing, and Xi’an with incremental cost-effectiveness ratios in terms of additional successfully treated patient being ¥1,861, ¥163, and ¥16,509, respectively. “This is the first cost-effectiveness study that evaluated linezolid against vancomycin in the treatment of methicillin resistant nosocomial pneumonia in the local contexts of China. The robustness of the base case findings in this analysis were further supported by the consistent cost-saving or cost-effective findings through a series of sensitivity and scenario analyses.” says lead author, Seng Chuen Tan, BPharm(Hons), MSc, Health Economics & Outcomes Research at IMS Health Asia-Pacific in Singapore.

Value in Health Regional Issues (ISSN 2212-1099) is a scientific journal that encourages and enhances the science of pharmacoeconomic/health economic and health outcomes research and its use in health care decisions. The journal is published up to three times a year with one issue focusing on the Asia region, one issue focusing on the Latin America region, and one issue focusing on the Central & Eastern Europe, Western Asia and Africa regions.

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

Follow Value in Health Regional Issues on Twitter: @ISPORJournals

Related Stories

Value in Health Regional Issues Expands Editorial Scope and Reveals Plans to Transition to Gold Open Access Model

Jan 23, 2024

Value in Health Regional Issues, an official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the expansion of its editorial scope and its plan to transition to a gold open access journal.

Empowering Change: Transforming Health Systems in Low- and Middle-Income Countries

Jan 22, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health Regional Issues that highlight innovative approaches to improving health outcomes in low- and middle-income countries through partnerships between health economics researchers and policy makers.

ISPOR’s Value in Health Regional Issues Receives Its First Impact Factor Score

Aug 7, 2023

Value in Health Regional Issues, the regionally focused journal of ISPOR, received its first-ever impact factor score this year. Value in Health, one of the top-ranked journals in the HEOR field, maintained its high ranking on the prestigious list of scholarly journals.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×